Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1636–1640. doi: 10.1128/aac.41.8.1636

Assessment of biliary excretion of piperacillin-tazobactam in humans.

J F Westphal 1, J M Brogard 1, F Caro-Sampara 1, M Adloff 1, J F Blicklé 1, H Monteil 1, F Jehl 1
PMCID: PMC163977  PMID: 9257733

Abstract

Piperacillin-tazobactam concentrations in serum and bile were measured intraoperatively in 10 patients undergoing cholecystectomy (group 1) and 5 cholecystectomized patients provided with external bile duct drainage (group 2). Each patient received a single intravenous dose of piperacillin at 4 g plus tazobactam at 0.5 g over 30 min. Drug concentrations in both serum and bile were measured by high-performance liquid chromatography. In group 1 patients, serum and bile specimens and gallbladder wall fragments were collected at mean times of 70 and 83 min postinfusion, respectively. The mean concentrations of piperacillin and tazobactam were, respectively, 69.1 +/- 41.5 (standard deviation) and 9.9 +/- 5.1 microg/ml in serum, 630.4 microg/ml (range, 24.8 to 1,194 microg/ml) and 11.8 microg/ml (range, 3.6 to 22 microg/ml) in choledochal bile, 342.3 microg/ml (range, 1.1 to 1,149 microg/ml) and 7.7 microg/ml, (range, 0.2 to 23.1 microg/ml) in gallbladder bile, and 49.3 microg/g (range, 9.7 to 223 microg/g) and 2.9 microg/g (range, 0.1 to 5.9 microg/g) in the gallbladder wall. In group 2 patients, the amounts of drugs recovered in bile drainage obtained over 12 h were 28.4 +/- 18.0 and 1.0 +/- 0.5 mg for piperacillin and tazobactam, respectively. Peak piperacillin and tazobactam concentrations in bile reached 358 +/- 242 and 10.8 +/- 4.2 microg/ml, respectively. Comparison of drug levels in serum and bile suggests an underlying active secretion process for piperacillin elimination into the bile, unlike that of tazobactam. From a therapeutic viewpoint, given the concentrations of tazobactam recorded in bile fluid and tissue, the addition of this beta-lactamase inhibitor to piperacillin therapy might be of interest in the management of biliary tract infections, mostly in patients at risk of mixed aerobic-anaerobic infections due to beta-lactamase-producing organisms.

Full Text

The Full Text of this article is available as a PDF (176.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexov M., Lister P. D., Sanders C. C. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob Agents Chemother. 1996 Nov;40(11):2468–2477. doi: 10.1128/aac.40.11.2468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Appelbaum P. C. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):29–38. doi: 10.1093/jac/31.suppl_a.29. [DOI] [PubMed] [Google Scholar]
  3. Bourgault A. M., England D. M., Rosenblatt J. E., Forgacs P., Bieger R. C. Clinical characteristics of anaerobic bactibilia. Arch Intern Med. 1979 Dec;139(12):1346–1349. [PubMed] [Google Scholar]
  4. Brogard J. M., Caro-Sampara F., Westphal J. F., Blickle J. F., Jehl F. Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation. Drugs Exp Clin Res. 1994;20(6):247–255. [PubMed] [Google Scholar]
  5. Brogard J. M., Jehl F., Blickle J. F., Dorner M., Arnaud J. P., Monteil H. Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. Int J Clin Pharmacol Ther Toxicol. 1990 Nov;28(11):462–470. [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Craig W. A., Vogelman B. Changing patterns of hospital infections: implications for therapy. Changing concepts and new applications of antibiotic pharmacokinetics. Am J Med. 1984 Jul 31;77(1B):24–28. doi: 10.1016/s0002-9343(84)80092-3. [DOI] [PubMed] [Google Scholar]
  8. England D. M., Rosenblatt J. E. Anaerobes in human biliary tracts. J Clin Microbiol. 1977 Nov;6(5):494–498. doi: 10.1128/jcm.6.5.494-498.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerecht W. B., Henry N. K., Hoffman W. W., Muller S. M., LaRusso N. F., Rosenblatt J. E., Wilson W. R. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med. 1989 Jun;149(6):1279–1284. [PubMed] [Google Scholar]
  10. Gutmann L., Kitzis M. D., Yamabe S., Acar J. F. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother. 1986 May;29(5):955–957. doi: 10.1128/aac.29.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacobs M. R., Aronoff S. C., Johenning S., Shlaes D. M., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jun;29(6):980–985. doi: 10.1128/aac.29.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jehl F., Gallion C., Monteil H. High-performance liquid chromatography of antibiotics. J Chromatogr. 1990 Oct 12;531:509–548. doi: 10.1016/s0378-4347(00)82293-8. [DOI] [PubMed] [Google Scholar]
  13. Jones R. N., Pfaller M. A., Fuchs P. C., Aldridge K., Allen S. D., Gerlach E. H. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489–494. [PubMed] [Google Scholar]
  14. Kornguth M. L., Monson R. A., Kunin C. M. The binding of penicillin antibiotics to a human liver protein. Arch Biochem Biophys. 1976 May;174(1):339–343. doi: 10.1016/0003-9861(76)90353-2. [DOI] [PubMed] [Google Scholar]
  15. Leleu G., Kitzis M. D., Vallois J. M., Gutmann L., Decazes J. M. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1994 Feb;38(2):195–199. doi: 10.1128/aac.38.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lister P. D., Prevan A. M., Sanders C. C. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother. 1997 Apr;41(4):721–727. doi: 10.1128/aac.41.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maddocks A. C., Hilson G. R., Taylor R. The bacteriology of the obstructed biliary tree. Ann R Coll Surg Engl. 1973 May;52(5):316–319. [PMC free article] [PubMed] [Google Scholar]
  18. Payne D. J., Cramp R., Winstanley D. J., Knowles D. J. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother. 1994 Apr;38(4):767–772. doi: 10.1128/aac.38.4.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pitt H. A., Postier R. G., Cameron J. L. Biliary bacteria: significance and alterations after antibiotic therapy. Arch Surg. 1982 Apr;117(4):445–449. doi: 10.1001/archsurg.1982.01380280037008. [DOI] [PubMed] [Google Scholar]
  20. Sörgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):39–60. doi: 10.1093/jac/31.suppl_a.39. [DOI] [PubMed] [Google Scholar]
  21. Tamai I., Maekawa T., Tsuji A. Membrane potential-dependent and carrier-mediated transport of cefpiramide, a cephalosporin antibiotic, in canalicular rat liver plasma membrane vesicles. J Pharmacol Exp Ther. 1990 May;253(2):537–544. [PubMed] [Google Scholar]
  22. Tsuji A., Terasaki T., Takanosu K., Tamai I., Nakashima E. Uptake of benzylpenicillin, cefpiramide and cefazolin by freshly prepared rat hepatocytes. Evidence for a carrier-mediated transport system. Biochem Pharmacol. 1986 Jan 15;35(2):151–158. doi: 10.1016/0006-2952(86)90508-3. [DOI] [PubMed] [Google Scholar]
  23. Turnidge J. D., Craig W. A. beta-Lactam pharmacology in liver disease. J Antimicrob Chemother. 1983 Jun;11(6):499–501. doi: 10.1093/jac/11.6.499. [DOI] [PubMed] [Google Scholar]
  24. Westphal J. F., Jehl F., Schloegel M., Monteil H., Brogard J. M. Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrob Agents Chemother. 1993 Jul;37(7):1488–1491. doi: 10.1128/aac.37.7.1488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES